Helping manufacturers realize biosimilar potential 

Understanding the complex coverage, payment, and regulatory landscape is critical to the success of any biosimilar manufacturer. As your strategic partner, our experts can anticipate reimbursement hurdles and create targeted strategies that maximize patient access at every stage of the product lifecycle. We develop the coding and reimbursement tools necessary—including compliant education programs—to minimize payment barriers and increase providers’ understanding of your product, while our policy and reimbursement experts help manufacturers stay informed on legal and compliance issues. 

Meet the experts 

Amanda Forys, MSPH 

Amanda Forys is Senior Director of Reimbursement Policy Insights Consulting at Xcenda. She has nearly 20 years of healthcare research and consulting experience, including reimbursement policy analytics with an emphasis on Medicare, commercial coverage, and payment policy. Her work has covered a wide range of topics, including biosimilars, bundled and episodic-based payment models, chronic disease management, oncology, end stage renal disease, and strategy for specialty pharmaceuticals.
Learn more about Amanda

Are biosimilars the new generics? 

With a handful of biosimilar treatments already approved by the Food and Drug Administration — and dozens of others coming down the pipeline — biosimilars are poised to disrupt the drug industry in terms of both care and cost. “In the next 10 years, I think we're going to catch up to Europe and see approvals speed up,” said Dave Picard, vice president of biosimilars and injectables at AmerisourceBergen. “For patients with high-cost, high-touch diseases, I think that biosimilars entering the space will improve access and affordability.” 
Grouping of vials

Start a conversation

We’re value drivers and problem solvers. Let us connect you with experts who understand your world and what success demands.
Contact us